Series B · Biotech

Immuneel Therapeutics closes Series B of more than ₹100 crore

The cell and gene therapy company will expand manufacturing and advance its treatment pipeline.

Immuneel Therapeutics announced the close of a Series B exceeding ₹100 crore on June 8. Singularity AMC and Rainmatter joined existing backers including Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital.

The company will expand manufacturing capacity, support commercialisation of its CAR-T therapy and advance its cell and gene therapy pipeline. It also plans international expansion across Asia-Pacific and the Middle East.

Use of funds

Expand cell therapy manufacturing capacity

Develop cell and gene therapy pipeline

Support commercialisation and international expansion

Funding history

Series B · This round>₹1B

Sources

  1. Immuneel Therapeutics closes Series B of more than ₹100 croreimmuneel.com · Jun 8, 2026